Biotech: Page 15
-
Permission granted by Antag Therapeutics
Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide drug data.
By Jonathan Gardner • Dec. 4, 2024 -
djgunner via Getty Images
Janux impresses Wall Street with new prostate cancer drug results
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to differentiated results, some analysts said.
By Ben Fidler • Dec. 3, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Pla2Na via Getty Images
Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M
The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to $558 million.
By Delilah Alvarado • Dec. 3, 2024 -
Daniel Tadevosyan via Getty Images
Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date
Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a key PDUFA date and Fate Therapeutics swapped CEOs.
By BioPharma Dive staff • Dec. 2, 2024 -
Kevin Dietsch / Staff via Getty Images
Pharma hopes Trump will bring change to the FTC. They may be disappointed.
Some in the drug industry expect more lenient merger enforcement under a second Trump administration. One former regulator argues that might not be the case.
By Kelly Bilodeau • Nov. 27, 2024 -
noparrit via Getty Images
Q&A // Brain drug revivalHow Intra-Cellular surprised Wall Street by breaking character
The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue forecast for its schizophrenia and depression medicine Caplyta.
By Jacob Bell • Nov. 27, 2024 -
Daniel Tadevosyan via Getty Images
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC disclosed negative Phase 2 results for its ALS drug candidate utreloxastat.
By BioPharma Dive staff • Nov. 27, 2024 -
Courtesy of Biohaven Ltd.
Biohaven muscle drug misses goal of SMA study, but advances in obesity
The setback likely removes one competitor to an emerging spinal muscular atrophy medicine from Scholar Rock, but sets the stage for a pair of readouts with implications for weight loss research.
By Ben Fidler • Nov. 25, 2024 -
Ivan Balvan via Getty Images
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved with a broad label that looks competitive to Pfizer's tafamidis.
By Ben Fidler • Nov. 22, 2024 -
Daniel Tadevosyan via Getty Images
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target in sight and an FDA veteran plans retirement.
By BioPharma Dive staff • Nov. 22, 2024 -
Andrii Yalanskyi via Getty Images
Lexicon to disband sales team, lay off 60% of staff
The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application for diabetes drug Zynquista.
By Ned Pagliarulo • Nov. 22, 2024 -
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive // Emerging biotechBiotech startups are built on venture capital. Track funding rounds here.
London-based Charm Therapeutics closed a $80 million Series B round this week to fund development of its drug for acute myeloid leukemia. It’s planning to enter the clinic in the first quarter of 2026.
By Gwendolyn Wu , Ben Fidler , Ned Pagliarulo , Julia Himmel • Updated Sept. 2, 2025 -
Jacob Bell/BioPharma Dive
Amgen picks prolific biotech founder Chang as new top scientist
Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to overcome the looming loss of exclusivity for some of its top-selling medicines.
By Kristin Jensen • Nov. 21, 2024 -
Permission granted by Versant Ventures
Versant startup sets out to make a new type of obesity drug
The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a treatment that can improve upon drugs like Wegovy and Zepbound.
By Gwendolyn Wu • Nov. 21, 2024 -
Popartic via Getty Images
Sage’s string of research failures continues
Negative results from a Huntington’s trial add to a calamitous year for Sage, which last month decided to overhaul its research, reconfigure its executive team and lay off a third of its staff.
By Jacob Bell • Nov. 20, 2024 -
Permission granted by Valora Therapeutics
Chasing new ‘checkpoints,’ startup Valora emerges from a Nobel winner’s lab
Built around research by Stanford scientist Carolyn Bertozzi and MIT researcher Jessica Stark, Valora Therapeutics is designing drugs to target glyco-immune checkpoints.
By Gwendolyn Wu • Nov. 20, 2024 -
Permission granted by Flagship Pioneering
Flagship, Pfizer alliance yields two more startup deals
Pfizer will work with Ampersand Biomedicines and Montai Therapeutics to find drugs for obesity and lung cancer, respectively, adding to collaborations it previously formed with other Flagship startups.
By Gwendolyn Wu • Updated Nov. 20, 2024 -
Daniel Tadevosyan via Getty Images
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer
The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless founded a new startup and Novartis licensed another radiopharma drug.
By BioPharma Dive staff • Nov. 19, 2024 -
Permission granted by Incyte
Incyte sinks on setback for drugs acquired in $750M buyout
The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its diversification plans.
By Ben Fidler • Nov. 19, 2024 -
Permission granted by Intellia Therapeutics
Gene editingCRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.
By Ned Pagliarulo • Nov. 18, 2024 -
koto_feja via Getty Images
Q&A // Brain drug revivalHow a Biogen drug set the stage for a new biotech targeting ALS
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke with BioPharma Dive about how the company came together.
By Jacob Bell • Nov. 15, 2024 -
Joey Sirmons / BioPharma Dive/BioPharma Dive
‘Find any advantage’: 3 biotech leaders on driving R&D success
“Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel hosted by BioPharma Dive.
By Jonathan Gardner • Nov. 15, 2024 -
Joey Sirmons / BioPharma Dive/BioPharma Dive
Emerging biotechSurviving in biotech’s new normal: 5 tips from industry VCs and CEOs
At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending and maintaining lines of sight to the clinic.
By Ned Pagliarulo , Delilah Alvarado • Nov. 15, 2024 -
Daniel Tadevosyan via Getty Images
Halozyme bids for Evotec; BeiGene gets a new name
The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first Lyfgenia revenue and Leerink built up its M&A team.
By BioPharma Dive staff • Nov. 15, 2024 -
Courtesy of Eisai
New Alzheimer's drugsEisai wins over European regulators on Alzheimer’s drug Leqembi
The EMA sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.
By Jacob Bell • Nov. 14, 2024
Previous
